Promastigote viability assay of Leishmania major when treated with 0.5 µM or 2 µM BMAP-28 variants.

L. major MHOM/SN/74/SD strain was treated with L-, RI- and D-BMAP-28 peptides for 4 hours. Viability was expressed as a percentage of untreated control cells. Three complete biological replicates were performed and the mean and standard deviation are shown. The percentage viability at 0.5 µM or 2 µM of each BMAP-28 peptide was calculated from the dose response curve performed (replication). The percentage viability at 0.5 µM or 2 µM of each BMAP-28 peptide was determined from the bar graph reported in Fig. 1A of Lynn et al. [5] (original). Unpaired t-tests untreated vs treated indicated significance.Promastigote viability assay of Leishmania major when treated with 0.5 µM or 2 µM BMAP-28 variants.